Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
Status:
Terminated
Trial end date:
2019-06-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is look at the safety of:
- Taking a specific combination of immunosuppressant drugs after liver transplantation
- Receiving one of three different doses of donor-alloantigen-reactive regulatory T cells
(darTregs) while taking this specific combination of drugs
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)